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ABSTRACT Stage III N2 nonsmall cell lung cancer (NSCLC) is a complex disease with poor treatment
outcomes. For patients in whom the disease is considered technically resectable, the main treatment
options include surgery (with neoadjuvant or adjuvant chemotherapy/neoadjuvant chemoradiotherapy
(CRT)) or CRT followed by adjuvant immunotherapy (dependent on programmed death ligand 1 status).
As there is no clear evidence demonstrating a survival benefit between these options, patient preference
plays an important role. A lack of a consensus definition of resectability of N2 disease adds to the
complexity of the decision-making process. We compared 10 international guidelines on the treatment of
NSCLC to investigate the recommendations on preoperatively diagnosed stage III N2 NSCLC. This
comparison simplified the treatment paths to multimodal therapy based on surgery or radiotherapy (RT).
We analysed factors relevant to decision-making within these guidelines. Overall, for nonbulky mediastinal
lymph node involvement there was no clear preference between surgery and CRT. With increasing extent
of mediastinal nodal disease, a tendency towards multimodal treatment based on RT was identified. In
multiple scenarios, surgery or RT-based treatments are feasible and patient involvement in decision-
making is critical.
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For many patients with stage III N2 NSCLC, radiotherapy or surgery are options and should be
discussed with the patient http://bit.ly/2Z39MW5
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Introduction
Stage III nonsmall lung cancer (NSCLC) with ipsilateral and/or subcarinal mediastinal lymphatic spread
(N2) represents a potentially curable disease, although prognosis remains poor with a 5-year overall
survival (OS) in the range of 15–40% [1–3]. The optimal treatment remains controversial due to a high
degree of heterogeneity among stage III N2 patients and a lack of a universally agreed definition on
resectability. The two main multimodal treatment options in this setting are chemoradiotherapy (CRT)
(with or without adjuvant immunotherapy) or surgery (with neoadjuvant or adjuvant chemotherapy (Ch)/
neoadjuvant CRT).
These treatment options may both be available for several decision criteria combinations, especially since
there is no clear randomised evidence suggesting one treatment regime is superior over another in terms
of OS [4, 5]. In such a setting, patient preference becomes even more important and the focus of the
decision-making process should include the patient experience, influenced by side effects and logistical
considerations (e.g. having to stay in the hospital with surgery or receiving daily treatments for several
weeks with radiotherapy (RT)). As shared decision-making is a complex process with various potential
pitfalls [6], patient decision aids will become increasingly helpful in these settings [7, 8]. Various factors
may influence the availability and suitability of available treatments [9] and a multitude of clinical decision
criteria can be implemented [10].
In clinical practice, it is important to recognise situations where the patient can be offered multiple
treatment options. The aim of this work was to identify which disease characteristics are essential in
current international guidelines for stage III N2 NSCLC and how they impact decision-making.
Methods
Guidelines available in English and German (based on spoken languages of authors) and published after
2009 were identified. The web-based search conducted in spring 2019 included: national guidelines
NSCLC, stage III N2 NSCLC and guidelines NSCLC. Current valid guidelines (American College of Chest
Physicians (ACCP) 2013 [11], British Thoracic Society (BTS) 2010 [12], European Society for Medical
Oncology (ESMO) 2015/2017 [13, 14], National Institute for Health and Care Excellence (NICE) 2011/
2019 [15, 16], National Comprehensive Cancer Network (NCCN) 2018 [17, 18], Spanish Society of
Medical Oncology (SEOM) [19], German S3 Guideline on Treatment of NSCLC [20], Chinese [21], Irish
[22] and Australian [23]) were identified, reviewed, and summarised analogous to a previous summary of
five selected guidelines [24]. The analysed guidelines were weighted equally and not evaluated for their
methodological quality. As such, statements regarding the quality of evidence for specific
recommendations and their consensus were not made.
The recommendations on stage III N2 NSCLC within the guidelines were reduced to recommendations
towards a definitive surgical approach (with neoadjuvant or adjuvant Ch/CRT), a definitive CRT approach
or no preference (no specific recommendation for either RT or surgery and both being options). Decision
criteria implemented were analysed and standardised if their meaning was not changed, as described by
PANJE et al. [25–27]. Universal criteria such as the ability to give informed consent were not included in
this analysis. In several instances, trial participation was a recommended option; this was excluded from
the decision tree analysis.
The final decision criteria implemented included: resectability (potentially resectable or not), lymph node
extent (single station, multistation and single zone, multizone), and lymph node volume (bulky,
nonbulky). In order to ensure comparability, simplifications of terminology were performed, while
attempting to keep the original statements as verbatim as possible. The resectability criterion used here
includes the possibility of surgical tumour removal with an R0 margin based on preoperative imaging, as
well as the required physical fitness for radical operative treatment. In the BTS and Irish guidelines, lymph
nodes are grouped by zones according to the International Association for the Study of Lung Cancer
(IASLC) lymph node map presented in the American Joint Committee on Cancer (AJCC) 7th edition,
whereas others (e.g. ESMO, German guidelines) used nodal stations. For the purposes of this analysis the
extent of mediastinal lymph node involvement was categorised as: 1) single station and therefore single
zone; 2) multistation, but limited to single zone; and 3) multizone. The obvious limitation is that the
primary multistation nodal involvement described in a guideline using nodal stations as a descriptor could
fall within a single zone or multiple zones (stations 2 and 4 single zone, stations 4 and 7 multizone).
Morphological characteristics of the lymph nodes were categorised into simplified categories: bulky and
nonbulky. There are different descriptions used to characterise nonbulky lymph nodes. These include lymph
node diameter less than 3 cm, easily measurable and defined lymph nodes free of major mediastinal
structures including the trachea and great vessels, or low-volume lymph nodes [12, 17, 18, 21, 28].
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The treatment of stage III N2 NSCLC is clearly multimodal. In multimodal treatment based on surgical
approach, to further simplify the comparison, there was no distinction between neoadjuvant and adjuvant
Ch as the benefit from preoperative Ch is similar to that of postoperative Ch and either approach is
justified [17, 18].
The resulting decision trees were analysed for consensus and dissent with the objective consensus
methodology [25, 29, 30].
Results
Ten guidelines were identified and converted into decision trees, as shown in the example in figure 1.
A total of three simplified criteria were used in the analysed guideline (table 1).
Discussion
The review of the existing guidelines revealed RT-based approaches as the most commonly recommended
treatment (based on these simplified criteria). For several parameter combinations, multimodal treatment
based on surgery is a recommended alternative, and in several instances, this was the treatment of choice.
The management of stage III N2 NSCLC is undergoing rapid evolution with the introduction of
immunotherapy. New evidence is being collected in ongoing clinical trials. The implementation in
international treatment guidelines is progressing; however, this has not directly affected the decision
between surgical and RT-based approaches.
The question of resectability and how it is defined is essential to decision-making for stage III N2 NSCLC.
Preoperative surgical evaluation can be challenging and depends on an individual surgeon’s expertise.
There are no definitive criteria to preoperatively confirm the resectability of disease. This is in part a
subjective decision based on a surgeon’s individual judgement at being able to achieve a clear resection
margin.
In many cases of preoperatively diagnosed N2 disease, neoadjuvant Ch or CRT are performed with the
aim of tumour downsizing and/or controlling local disease. Neoadjuvant treatment may also come with a
risk of forming mediastinal soft tissue fibrosis, potentially complicating subsequent hilar and mediastinal
dissections. Therefore, when multimodal regimes are considered, even closer interdisciplinary collaboration
by an experienced team is essential.
LN extent: multistation single zone
LN extent: single station
LN extent: multizone
RT
LN volume: nonbulky
LN volume: bulky
LN volume: nonbulky
LN volume: bulky
S
RT
S
RT
RT
Pot. resectable: yes
Pot. resectable: no
Stage III N2
FIGURE 1 Example of the simplified decision tree representing the 2010 British Thoracic Society guideline. Pot.: potentially; LN: lymph node;
RT: radiotherapy; S: surgery.
TABLE 1 The use of simplified decision criteria per analysed guideline
Criterion ACCP BTS ESMO NICE NCCN SEOM German Chinese Irish Australian
Resectability • • • • • • • • • •
Lymph node
volume
• • • • • • •
Lymph node
extent
• • • • • •
ACCP: American College of Chest Physicians; BTS: British Thoracic Society; ESMO: European Society for
Medical Oncology; NICE: National Institute for Health and Care Excellence; NCCN: National
Comprehensive Cancer Network; SEOM: Spanish Society of Medical Oncology.
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There are also reports of neoadjuvant treatment with immunotherapy in NSCLC [31, 32]. BOTT et al. [31]
confirmed a major pathological response in 9 of 20 (45%) patients treated with nivolumab in NSCLC stage
I–IIIA being enrolled. In this report, more than a half of the minimally invasive intended operations were
converted to thoracotomy due to hilar inflammation and fibrosis. While there was no operative mortality,
perioperative morbidity was present and mostly due to atrial arrhythmia. Similarly, FORDE et al. [32]
reported a major pathological response on histologic examination in 45% of examined tumours.
Interestingly, only two patients had a radiologic partial response, due to postulated immune-cell
infiltration into the tumour, rather than true tumour mass. To define the role of neoadjuvant
immunotherapy long-term follow-up of currently recruiting phase III studies, such as ClinicalTrials.gov
identifier: NCT02998528, need to be evaluated. The purpose of this neoadjuvant study is to compare
nivolumab plus Ch and Ch alone in terms of safety and effectiveness, and to describe nivolumab plus
ipilimumab’s safety and effectiveness in treating resectable NSCLC. The estimated completion date is
November 2028.
Not surprisingly, for unresectable tumours RT-based approaches are recommended. There are randomised
controlled trial data confirming a significant improvement with adjuvant immunotherapy following
definitive CRT in unresectable stage III N2 NSCLC [33]. The definition of unresectable in this trial was
left to the discretion of local tumour boards and was likely to have been highly variable. How
immunotherapy in both RT-based multimodality treatment and surgical-based multimodality treatment
will impact future trends remains undefined but is expected to become a critical aspect in future
decision-making as evidence develops.
In general, with increasing volume or extent of N2 disease, there is an increasing trend towards therapy
based on RT. There is no consensus on a unified cut-off for nodal volume related to surgery. In patients
with low-volume mediastinal N2 disease (especially single station) surgery was a common
recommendation. Four of the analysed guidelines clearly recommended surgery in potentially resectable
tumours with single station nonbulky involvement. In this setting, the other six guidelines declared no
preference between surgery and RT. In potentially resectable tumours with multistation but single-zone,
nonbulky mediastinal involvement, significant variation was observed: four guidelines recommended
surgery, two recommended RT and four declared no preference (figures 2 and 3). For resectable tumours
with bulky lymph nodes the overwhelming majority of analysed guidelines recommended a RT-based
approach. The recommendation towards surgery in a few decision trees for this particular constellation
might potentially be due to a lack of explicitly naming bulky disease within selected guidelines.
The Intergroup study (INT 0139) compared treatment outcomes after definitive Ch/RT and Ch/RT
followed by surgery in pre-therapeutically diagnosed N2 disease considered to be resectable. A significantly
better progression-free survival (PFS) was shown (29% versus 19%; p=0,02). However, OS was not
significantly different (3-year OS 38% versus 33%). Based on the relatively high mortality after
pneumonectomy (22%) compared to lobectomy (1%), it might be reasonable to perform definitive CRT if
LN extent: multistation single zone
LN extent: multizone
RT
LN extent: single station
LN volume: nonbulky
NP NCCN ACCP
NCCN ACCP
NCCN ACCP
NCCN ACCP
NCCN ACCP
ESMO
S
S
NP
RT
NP
RT
RT
S
S
NP
RT
S
NP
RT
S
NP
LN volume: bulky
LN volume: nonbulky
LN volume: bulky
LN volume: nonbulky
LN volume: bulky
Pot. resectable: yes
Pot. resectable: no
Stage III N2
ESMO
NICE BTS
BTS
NICE
ESMO
ESMO
BTS
BTS
ESMOBTS
NICE
NICE
ESMOBTS
NICE
NICE
NCCN ACCP
FIGURE 2 Demonstration of all combinations of simplified criteria. Pot.: potentially; LN: lymph node; RT: radiotherapy; NP: no preference;
S: surgery.
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the surgery does require a pneumonectomy. In a post hoc analysis, the OS of lobectomy patients from the
surgical arm was significantly better than the CRT arm. It is widely debated how much weight can be
applied to this post hoc analysis, as excluding selected patients least suitable for RT might have resulted in
similar improvements. Within this trial, some patients requiring pneumonectomy were operated in
low-volume centres and may have contributed to the high pneumonectomy mortality. Lower mortality
rates for post-induction pneumonectomy have since been published from high volume centres as reported
by CASIRAGHI et al. [34] although these findings are not consistent, which was shown by D’AMATO et al.
[35]. These factors further cement the need for a multidisciplinary discussion with experienced clinicians.
The meta-analysis by PÖTTGEN et al. [36] found no significant difference between bimodal treatments
related to OS. There was heterogeneity across studies at 2 years, resulting from the rate of performed
pneumonectomies. The increased mortality following pneumonectomy was not confirmed in the
ESPATUE trial. Comparisons between surgery and RT are complicated by early perioperative mortality of
surgical patients with potential advantages in survival later on [37].
A meta-analysis by MCELNAY et al. [5] also compared trimodality treatment with CRT and surgery versus
definitive CRT. It combined the data from the INT 0139 trial and a study from SORENSEN et al. [39]
comparing induction Ch followed by RT versus induction Ch followed by surgery followed by RT. Both
studies were given equal weighting in the meta-analysis and the pooled hazard ratio for death in the surgery
group was 0.87 (CI 0.75–1.01; p=0.068) with no statistical evidence of heterogeneity (I2=0%, p=0.976).
Trimodal therapy was associated with a trend towards improved survival compared to bimodal treatments.
The 2019 NICE guidelines addressed the optimal management of potentially resectable stage III N2
NSCLC. Their analysis compared CRT followed by surgery (CRS), CRT, and chemotherapy and surgery
(CS). The meta-analysis could not distinguish the odds of survival across the treatment groups at 4 and
5 years. However, there was a strong but statistically insignificant trend towards improved survival with
CRS (in line with the trends from meta-analyses). CRS was associated with longer PFS than CRT/CS at 4
and 5 years (high quality evidence) with an average of a 4.5-month improvement. There were fewer grade
3+ adverse events with CRS than with CR/CS. The NICE guideline group also undertook cost-effectiveness
modelling, concluding that CRT is more cost effective than CS (incremental cost-effectiveness ratio of £53
000 per quality-adjusted life-year) and CRS is more cost effective than CRT (incremental cost-effectiveness
ratio of £17 800 per quality-adjusted life-year). This, therefore, is the first guideline to specifically
recommend trimodality treatment over the others in resectable N2 NSCLC. The guideline group
recommended that for patients fit enough for multimodality treatment and considered to be resectable,
induction CRT followed by surgery should be considered. This is a highly significant change from previous
NICE recommendations and a significant change in UK practice, where only 1.1% of N2 patients currently
receive trimodality treatment [38]. Such practice would require careful and considered implementation
within agreed protocols through high volume centres where outcomes are monitored closely.
The comparison between surgery and RT after induction Ch showed no differences in OS [1]. However,
the Chinese, BTS and the NICE guidelines are the only ones to recommend surgical resection over RT
with disease involvement of two nodal stations if involved lymph nodes are all smaller than 3 cm. The
Irish guideline only considers surgery in nonbulky single-zone N2 disease. This statement is based on
studies suggesting a survival benefit with a Ch plus surgery protocol. The BTS guideline restricts the
mediastinal involvement to single zone, whereas the Chinese does not differentiate this issue any further.
The only criterion described in the NICE guideline is resectability. Due to the simplification used to
compare the guidelines within the decision trees, all potentially resectable tumours are therefore treated
LN extent: multistation single zone
LN extent: single station
LN extent: multizone
100% RT
LN volume: nonbulky
LN volume: bulky
LN volume: nonbulky
LN volume: bulky
60%: NP
70%: RT
No consensus
80%: RT
Pot. resectable: yes
Pot. resectable: no
LN volume: nonbulky
LN volume: bulky 80%: RT
Stage III N2
50%: RT
FIGURE 3 Demonstration of the majority recommendations for each parameter combination. Pot.: potentially; LN: lymph node; RT: radiotherapy;
NP: no preference; no consensus: a majority preference among the three options was not identified (four recommended surgery, two RT and four
declared NP).
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with surgery. We are aware of potential limitations of the interpretation of the comparison due to the lack
of a more specific description of mediastinal lymph nodes status. It is controversial whether surgery
should be recommended in multizone bulky N2 NSCLC disease. The used criteria on mediastinal lymph
node extent does not allow for a differentiated categorisation between single zone and single station. This
is why the Chinese guideline is interpreted as recommending surgery for multistation single-zone disease
and RT for multistation multizone disease. The Chinese guideline used two “sets” of enlarged, not fused
lymph nodes to define a cut-off. For the purpose of this analysis, we categorised this as multistation single
zone. The Australian guideline was also simplified; the recommended treatments were RT with surgery,
reserved for rare cases with low-volume mediastinal lymph node involvement.
While some of these simplifications can be questioned, the authors believe that specialty bias did not play
a significant role, as we included two thoracic surgeons and two radiation oncologists. The big picture of
this result is that multiple options are available in multiple situations; this result would probably not
change by changing individual interpretations or by including potentially missed guidelines.
The large variability of recommendations among these guidelines may have multiple potential reasons. These
may include different methodologies used to develop the guidelines, local traditions, incomplete definition of
decision criteria (e.g. only broadly specified lymph node involvement, lacking definition of resectability) as
well as different time of guideline publication 2009–2019 and different studies included in analyses.
The evidence base in this setting has several severe limitations. A number of key trials (Intergroup and
European Organisation for Research and Treatment of Cancer) date from a time before routine positron
emission tomography, CT and endoscopic nodal staging and advances in surgical and RT techniques are not
accounted for. Some trials, such as the ESPATUE trial had a heterogeneous study population (e.g. one-third
of patients with T4 N0/1) further hampering definitive conclusions on the management of N2 disease.
Many patients with resectable stage III N2 NSCLC have a number of treatment options available to them,
assuming adequate physiological reserve for treatment: definitive CRT (± adjuvant immunotherapy),
surgical resection followed by adjuvant Ch, induction Ch followed by surgery and induction CRT followed
by surgery. The majority of guidelines note that no treatment has been shown to be superior to another
and therefore multiple options exist. Furthermore, a clear definition of resectability remains elusive. There
are randomised controlled data, meta-analyses and guideline group network meta-analyses (NICE) that
suggest an improvement in PFS with CRT followed by surgery over definitive CRT for resectable tumours.
There are meta-analyses data confirming a strong suggestion towards improved OS and post hoc analysis
data suggesting a significant OS improvement if lobectomy is performed. All of this information is
followed by a series of questions and controversies. Additionally, significant questions remain on how to
interpret the data in the era of immunotherapy after definitive CRT. Definitive evidence for the optimal
treatment of resectable stage III N2 NSCLC remains elusive.
Conclusion
The optimal strategy in resectable III N2 NSCLC remains unresolved. Most guidelines consider surgical
approaches to be a treatment option, and in several instances, surgery is the preferred treatment option in
patients with low-volume mediastinal nodal involvement. In more advanced cases, most guidelines
recommend multimodal treatment based on RT. Immunotherapy has an established role following CRT in
unresectable disease and continues to be explored in resectable disease in clinical trials. Patient preference
should be central to decision-making where both surgical and RT-based options are available.
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